1-4 of 4
Mark A. Ashwell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B270: Discovery and preliminary characterization of novel tyrosine kinase inhibitors with selectivity to BTK.

Nivedita D. Namdev, Susan Cornell-Kennon, Yi Yu, Jason Hill, Cathy Bull, Laurie Volak, Jianqiang Wang, Deirdre Lowe, Xuibin Gu, Steffi Koerner, Magdi Moussa, David Vensel, Yanbin Liu, Hui Wu, Chang-Rung Chen, Daniel T. Dransfield, Mark A. Ashwell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B270.
https://doi.org/10.1158/1535-7163.TARG-13-B270
Published: 01 November 2013
View article titled, Abstract B270: Discovery and preliminary characterization of novel tyrosine kinase inhibitors with selectivity to BTK.
Journal Articles

Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.

Thomas C.K. Chan, Jean-Marc Lapierre, Mark A. Ashwell, Dennis S. France, Chang-Rung Chen, Susan Cornell-Kennon, Cathy Bull, Sudhi Eathiraj, Rocio Palma, Yanbin Liu, Sapna Makhija, Carol Waghorne, Ron Savage, Kosaku Fujiwara
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A230.
https://doi.org/10.1158/1535-7163.TARG-11-A230
Published: 12 November 2011
View article titled, Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.
Journal Articles

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

Neru Munshi, Sébastien Jeay, Youzhi Li, Chang-Rung Chen, Dennis S. France, Mark A. Ashwell, Jason Hill, Magdi M. Moussa, David S. Leggett, Chiang J. Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1544–1553.
https://doi.org/10.1158/1535-7163.MCT-09-1173
Published: 09 June 2010
View article titled, ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
Open the PDF for ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Abstract A139: Discovery and biological profiling of potent fibroblast growth factor receptor (FGFR) kinase inhibitors derived from in silico design with in vivo antitumor activity against FGFR2‐dependent human tumors

Chang‐Rung Chen, Syed Ali, Rocio Palma, Sudharshan Eathiraj, Craig Bates, Mayank Bhavsar, Chris Brassard, Jennifer O. Brown, Cathy Bull, Li Huang, Darin Kizer, Yanbin Liu, Denise McSweeney, Magdi Moussa, Enkeleda Nakuci, Manish Tandon, Dave Vensel, Erika Volckova, Jianqiang Wang, Neil Westlund, Hui Wu, Rui‐Yang Yang, Dennis S. France, Mark A. Ashwell, Thomas C.K Chan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A139.
https://doi.org/10.1158/1535-7163.TARG-09-A139
Published: 10 December 2009
View article titled, Abstract A139: Discovery and biological profiling of potent fibroblast growth factor receptor (FGFR) kinase inhibitors derived from <em>in silico</em> design with <em>in vivo</em> antitumor activity against FGFR2‐dependent human tumors